Evolution of Protease and Reverse Transcriptase Inhibitor Resistance-Associated Mutations in HIV-1-Infected Protease Inhibitor-Treated Patients with Persistent Low Viraemia

Abgrall S. , Duval X. , Joly V. , Descamps D. , Matheron S. , & Costagliola D. Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy. Clinical Infectious Diseases 2003; 37: 1517–1526.

Deeks S.G. Durable HIV treatment benefit despite low-level viremia – reassessing definitions of success or failure. Journal of the American Medical Association 2001; 286: 224–226.

Aleman S. , Soderbarg K. , Visco-Comandini U. , Sitbon G. , & Sonnerborg A. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 2002; 16: 1039–1044.

Karlsson A.C. , Younger S.R. , Martin J.N. , Grossman Z. , Sinclair E. , Hunt P.W. , Hagos E. , Nixon D.F. , & Deeks S.G. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 2004; 18: 981–989.

Nettles R.E. , Kieffer T.L. , Simmons R.P. , Cofrancesco J. Jr. , Moore R.D. , Gallant J.E. , Persaud D. , & Siliciano R.F. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clinical Infectious Diseases 2004; 39: 1030–1037.